Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
688336
Rank in Stocks
#3772
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a... Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a biopharmaceutical enterprise operating in China. This company is thoroughly engaged in the full lifecycle of antibody-based medicines, from their initial research and development to their production and subsequent market introduction. Its current portfolio includes YISAIPU, a tumor necrosis factor inhibitor utilized for treating rheumatic ailments; Xenopax, a recombinant humanized anti-CD25 monoclonal antibody delivered via injection; and Cipterbin, an anti-HER2 monoclonal antibody. Furthermore, the organization is actively progressing novel treatments designed for autoimmune disorders, various cancers, and other health issues. Established in 2002, its main offices are situated in Shanghai, China.
Share Price
$4.87
Market Cap
$4.36B
Change (1 day)
-5.47%
Change (1 year)
-15.62%
Country
CN
Trade Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
Category
Healthcare
Stock split history for Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd stock (symbol: 688336) underwent a total of 1 stock splits.
The most recent stock split occurred on Jun 18, 2026.
One 688336 share bought prior to Jun 18, 2026 would equal to 1.45 688336 shares today.
The most recent stock split occurred on Jun 18, 2026.
One 688336 share bought prior to Jun 18, 2026 would equal to 1.45 688336 shares today.
Stock split list
| Year | Split | Multiple | Cumulative Multiple |
|---|---|---|---|
| 2026-06-18 | 29:20 | x1.45 | x1.45 |
Stock splits for similar companies or competitors
| Company | Number of stock splits | Cumulative Multiple | Country |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 1 | x100 |
BE
|
|
| 0 | - |
NL
|
